Personalized and Precision Medicine (PPM) as a unique healthcare model through biodesign-inspired bio- and chemical engineering applications to secure the human healthcare and biosafety

Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through biodesign-inspired bio- and chemical engineering applications to secure the human healthcare and biosafety

Abstract:

A new systems approach to subclinical and/or diseased states and wellness resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM). To achieve the implementation of PPM concept, it is necessary to create a fundamentally new strategy based upon the biomarkers and targets to have a unique impact for the implementation of PPM model into the clinical practice and pharma & medicinal chemistry bioindustry. In this sense, the translation of discoveries into therapies has not kept pace with medical need. It would be extremely useful to integrate data harvesting from different databanks for applications to provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes.

Translational researchers, biodesigners, bio- and chemical engineers, and manufacturers are beginning to realize the promise of PP. Biodesign, bio- and chemical engineering, and nanobiotechnologies are being integrated into diagnostic and therapeutic tools to manage an array of PPM-guided conditions to customize therapeutic management. So, partnering and forming strategic alliances between researchers, bio-designers, bio- and chemical engineers, clinicians, business, regulatory bodies and government can help ensure an optimal development program that leverages the Academia and industry experience and FDA’s new and evolving toolkit to speed our way to getting new tools into the innovative markets.

Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to support the advent of PPM. It is urgently needed to discover, to develop and to create new (targeted and/or smart/intelligent) drugs being based on design-driven bio- and chemical engineering. With the support of nanotechnology, new targeted therapeutic agents and biomaterials, or aid the development of assays for disease biomarkers and identification of potential biomarker-target-ligand (drug) tandems to be used for the targeting, PPM is making phenomenal steps in the future to come.

Scaling up from a laboratory reaction to an industrial process is the main challenge for chemical and bioengineers resulting in the optimization at many levels. Moreover, developing and optimising chemical and biotechnological processes plays a key role in modern society. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM and design-driven translational applications to elicit the content of the new trend. The latter would provide a unique platform for collaboration among thought leaders and stakeholders in government, academia, industry, foundations, and disease and patient advocacy with an interest in improving the system of healthcare delivery on one hand and drug discovery, development, and translation, on the other one, whilst educating the policy community about issues where biomedical science and policy intersect. So, the Grand Change and Challenge to secure our Health and Wellness are rooted not in Medicine, and not even in Science! Just imagine WHERE?! In the upgraded Hi-Tech Culture!

Biography:

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology. In 2001, Suchkov maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1989 through 1995, Dr Suchkov was being a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004 - a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI). In 1993-1996, Dr Suchkov was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.

At present, Dr Sergey Suchkov, MD, PhD, is:
● R&D Director of the National Center for Human Photosynthesis, Aguascalientes, México
● The Russian Academy of Natural Sciences, Moscow, Russia
● Member, New York Academy of Sciences, USA
● New York Academy of Sciences, USA
● Secretary General, United Cultural Convention (UCC), Cambridge, UK
Dr Suchkov is a member of the:
● American Chemical Society (ACS), USA;
● American Heart Association (AHA), USA;
● European Association for Medical Education (AMEE), Dundee, UK;
● EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU;
● ARVO (American Association for Research in Vision and Ophthalmology);
● ISER (International Society for Eye Research);
● Personalized Medicine Coalition (PMC), Washington, DC, USA